(Total Views: 715)
Posted On: 08/25/2021 10:35:40 AM
Post# of 22467
Positive takes of today's PR
- India is still in place
- in talks with a partner to develop
- a new 3rd generation proprietary perovskite quantum dot solar cell technology developed by Solterra/QMC
- we have now developed a point of care test platform (POCT)
- We are currently developing 1) LFTs (lateral flow test kits) for TBI (traumatic brain injury, aka concussions), 2) a multiplex test that detects Covid-19, Flu and RSV (Respiratory Syncytial Virus), and 3) a vaccine validator to thwart counterfeit vaccines and validate vaccine efficac
- the Company has signed a term sheet with a Canada-based biotech company that has identified and has a patent-pending on several biomarker candidates that will be used to develop the TBI POCT.
- the POCT market technology is intended to part of our immediate commercialization focus.
- We are in the process of negotiating the final terms that include the payment milestones required for QMC to design, develop, shepherd the FDA approval process, and produce the test kits.
- I can assure you that we intend to work tirelessly to restore the Company’s reporting and trading status.
Negative takes:
- increasing authorized shares (nut necessary to relist)
- no mention of using those share for pasaca buy out
-shutting down QMC Healthid (what of it's part of the Innova ecosystem)
- QMC Verify (previously QMC Ledger we have made the decision to retain this technology but to defer its further development and commercialization until the company has achieved a sustainable revenue model or strategic funding to support this technology.
- If adequate working capital is not available, we may be forced to curtail operations, which would cause you to lose your entire investment.
- India is still in place
- in talks with a partner to develop
- a new 3rd generation proprietary perovskite quantum dot solar cell technology developed by Solterra/QMC
- we have now developed a point of care test platform (POCT)
- We are currently developing 1) LFTs (lateral flow test kits) for TBI (traumatic brain injury, aka concussions), 2) a multiplex test that detects Covid-19, Flu and RSV (Respiratory Syncytial Virus), and 3) a vaccine validator to thwart counterfeit vaccines and validate vaccine efficac
- the Company has signed a term sheet with a Canada-based biotech company that has identified and has a patent-pending on several biomarker candidates that will be used to develop the TBI POCT.
- the POCT market technology is intended to part of our immediate commercialization focus.
- We are in the process of negotiating the final terms that include the payment milestones required for QMC to design, develop, shepherd the FDA approval process, and produce the test kits.
- I can assure you that we intend to work tirelessly to restore the Company’s reporting and trading status.
Negative takes:
- increasing authorized shares (nut necessary to relist)
- no mention of using those share for pasaca buy out
-shutting down QMC Healthid (what of it's part of the Innova ecosystem)
- QMC Verify (previously QMC Ledger we have made the decision to retain this technology but to defer its further development and commercialization until the company has achieved a sustainable revenue model or strategic funding to support this technology.
- If adequate working capital is not available, we may be forced to curtail operations, which would cause you to lose your entire investment.
(1)
(0)
